Thyroid Eye Disease: Current Perspectives on Multidisciplinary Management

1400 6th Ave,Seattle WA 98101

04 May, 2023

Description

Activity ChairTerry J. Smith, MD Frederick G.L. Huetwell Professor Ophthalmology and Visual Sciences Professor of Internal Medicine University of Michigan Medical School Ann Arbor, MI FacultyGiuseppe Barbesino, MD Assistant Professor of Medicine Harvard Medical School Associate Physician Massachusetts General Hospital Boston, MA Christian Nasr, MD, FACE Chief of Endocrinology Banner University Medical Group Clinical Professor Department of Internal Medicine Division of Endocrinology The University of Arizona College of Medicine – Phoenix Phoenix, AZ Prem S. Subramanian, MD, PhD Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology Professor of Ophthalmology, Neurology, and Neurosurgery University of Colorado School of Medicine Vice Chair for Academic Affairs Division Head, Neuro-Ophthalmology University of Colorado Sue Anschutz-Rodgers Eye Center Aurora, CO OverviewThyroid eye disease (TED) is a multifactorial autoimmune disease with widely varied signs and symptoms. It is believed to result from stimulation of several receptors located in the orbital fibroblasts and is usually associated with hyperthyroidism. However, 5% of patients with TED have hypothyroidism, and 5% have no sign of thyroid disease; thus, it is frequently misdiagnosed. Misdiagnosis can place patients at risk for disfigurement and permanent vision loss, because treatment is most effective during the initial active phase of the disease. Multidisciplinary management of the disease is necessary and involves endocrinologists, ophthalmologists, oculoplastic surgeons, as well as other healthcare providers. In this case-based CME activity, an expert panel will help healthcare professionals involved in the management of TED to recognize the pathogenesis of TED and the role of insulin-like growth factor-1 receptor, assess methods to improve differential diagnosis, review the benefits and limitations of available therapies, and implement practices and procedures that improve the multidisciplinary management of patients with this baffling and potentially devastating disease. Agenda7:00 PM Registration and Dinner 7:30 PM Introduction Terry J. Smith, MD 7:35 PM Thyroid Eye Disease: Insulin-like Growth Factor-1 Receptor as a Key Mediator of Disease Terry J. Smith, MD 7:45 PM Panel Discussion: Diagnosing a Hidden Disease Moderated by Christian Nasr, MD 8:00 PM Case Discussion: Differential Diagnosis Giuseppe Barbesino, MD 8:05 PM Thyroid Eye Disease Treatment: What the Endocrinologist Needs to Know Prem S. Subramanian, MD, PhD 8:25 PM Case Discussion: Treating Thyroid Eye Disease Giuseppe Barbesino, MD 8:35 PM Panel Discussion Moderated by Terry J. Smith, MD 8:45 PM Posttest and Question & Answer 9:00 PM Conclusion Learning ObjectivesUpon successful completion of this activity, participants should be better able to: Recognize the role of insulin-like growth factor-1 receptor in the pathogenesis of TED.Assess modalities that can improve the differential diagnosis of TED.Review the benefits and limitations of available therapies used in the treatment of TED.Implement practices and procedures that improve the multidisciplinary management of patients with TED.Target AudienceThe intended audience for this activity is endocrinologists and other healthcare professionals involved in the management of patients with TED.